A rare case of cardiac toxicity in a patient with imatinib treatment: Case report
Authors:
- 11 June 2020
- journal article
- case report
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 18 (3) , 792-794
Abstract
Imatinib, a tyrosine kinase inhibitor, primarily used to treat chronic myeloid leukemia, has shown a survival benefit in gastrointestinal stromal tumors (GISTs). The most common toxicities of imatinib include fluid retention, diarrhea, nausea, fatigue, muscle cramps, abdominal pain, and rash. Imatinib-related cardiotoxicity is a rare condition, and its clinical severity varies between asymptomatic mild ventricular dysfunction and severe congestive heart failure (CHF). We report the case of a 64-year-old woman with a history of GIST who presented to our clinic with rapidly progressive dyspnea. After 8 weeks of imatinib treatment, the patient developed CHF. Echocardiography showed decreased ejection fraction. Imatinib was stopped and diuretic therapy was started. Two weeks later, she died. Cardiac shock was her cause of death.Keywords
This publication has 6 references indexed in Scilit:
- A gist of gastrointestinal stromal tumors: A reviewWorld Journal of Gastrointestinal Oncology, 2012
- Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylateCancer, 2009
- Congestive heart failure is a rare event in patients receiving imatinib therapyBlood, 2007
- Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology, 2007
- Cardiotoxicity of the cancer therapeutic agent imatinib mesylateNature Medicine, 2006
- Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor ReceptorsThe Journal of Pharmacology and Experimental Therapeutics, 2000